Oral Abstracts—Tuesday, September 25, 2018
OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)

https://doi.org/10.1016/j.jtho.2018.08.291Get rights and content
Under an Elsevier user license
open archive

Cited by (0)